Live Chat

Live Chat

BD MAX enteric assays

Enteric pathogens causing diarrhea account for more than 2 million deaths annually

Globally, 1.7 billion cases of diarrhea account for more than 2 million deaths annually. Children less than 5 years of age are particularly at risk, with 760,000 deaths each year.1 In the United States, more than 375 million episodes of diarrhea occur, resulting in 900,000 hospitalizations and 6,000 deaths annually.2

Current stool-culture–based testing for enteric pathogens is complex and time consuming. Immunoassay methods are available for some but not all of the major bacterial pathogens and therefore, do not alleviate the burden of culture.

In addition to creating a large burden for the laboratory, this greatly complicates patient management, since specific causative agents are not identified when a patient is first seen by a physician.

More than 90% of cultures are negative,3 and their results are not reported for at least two to three days.

Solution


BD MAX enteric solutions aim to significantly reduce materials and labor for the stool bench by offering a broad menu of enteric pathogen panels and greatly decreasing the time to result for a broad range of enteric pathogens.

How we help

BD MAX enteric solutions aim to significantly increase diagnostic accuracy for enteric pathogens compared to most conventional methods.

Panels


BD MAX enteric bacterial panel (targets Salmonella spp., Campylobacter spp., Shigella spp. and enteroinvasive E. coli)
This panel addresses approximately 95% of bacterial organisms causing infectious gastroenteritis.

BD MAX enteric parasite panel (targets Giardia lamblia and Entamoeba histolytica)
This panel can be used in conjunction with EBP or as a standalone assay. It provides flexible panel options for molecular testing, potentially improving time to result and accuracy, and eliminates labor-intensive manual processes.

BD MAX system

The BD MAX system helps redefine staff productivity with a fully integrated, automated molecular platform capable of running both FDA-cleared and open system assays efficiently and flexibly.


References
  1. World Health Organization. Diarrhoeal disease. World Health Organization Web site. http://www.who.int/mediacentre/factsheets/fs330/en/. Published April 2013. Accessed March 30, 2017.
  2. World Gastroenterology Organisation. WGO practice guideline - acute diarrhea. World Gastroenterology Organisation Web site. http://www.worldgastroenterology.org/guidelines/global-guidelines/acute-diarrhea. Accessed March 30, 2017.
  3. Beal SG, Mesfin M, Ciurca J, et al. Evaluation of costs, technologists time and turn-around times for conventional stool cultures. Paper presented at: American Society for Microbiology 2013 General Meeting; May 18-21, 2013; Denver, CO.

This site uses cookies. If you click accept cookies then all cookies will be written. Please review our cookies policy and configure your cookies for your experience.